GB0316294D0 - Conjugated biological molecules and their preparation - Google Patents

Conjugated biological molecules and their preparation

Info

Publication number
GB0316294D0
GB0316294D0 GBGB0316294.8A GB0316294A GB0316294D0 GB 0316294 D0 GB0316294 D0 GB 0316294D0 GB 0316294 A GB0316294 A GB 0316294A GB 0316294 D0 GB0316294 D0 GB 0316294D0
Authority
GB
United Kingdom
Prior art keywords
group
general formula
protein
compound
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0316294.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abzena UK Ltd
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27742023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0316294(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Priority to GBGB0316294.8A priority Critical patent/GB0316294D0/en
Publication of GB0316294D0 publication Critical patent/GB0316294D0/en
Priority to EP20100175143 priority patent/EP2277550B1/en
Priority to PL10175140T priority patent/PL2253330T3/pl
Priority to EP10175140.2A priority patent/EP2253330B1/en
Priority to KR1020067000278A priority patent/KR101152500B1/ko
Priority to DK04743335T priority patent/DK1648518T3/da
Priority to DK09167191.7T priority patent/DK2133099T3/en
Priority to ES10175143.6T priority patent/ES2542531T3/es
Priority to US10/564,340 priority patent/US7595292B2/en
Priority to CN2010101399434A priority patent/CN101792525B/zh
Priority to JP2006518372A priority patent/JP4958549B2/ja
Priority to ES10175140.2T priority patent/ES2549427T3/es
Priority to DE602004022824T priority patent/DE602004022824D1/de
Priority to AU2004257448A priority patent/AU2004257448B2/en
Priority to DK10175143.6T priority patent/DK2277550T3/en
Priority to EP09167191.7A priority patent/EP2133099B1/en
Priority to AT04743335T priority patent/ATE440620T1/de
Priority to ES04743335T priority patent/ES2331004T3/es
Priority to CN2004800198144A priority patent/CN1822860B/zh
Priority to EP04743335A priority patent/EP1648518B1/en
Priority to DK10175140.2T priority patent/DK2253330T3/en
Priority to PCT/GB2004/002994 priority patent/WO2005007197A2/en
Priority to ES09167191.7T priority patent/ES2632515T3/es
Priority to PL04743335T priority patent/PL1648518T3/pl
Priority to US12/458,931 priority patent/US7939630B2/en
Priority to AU2010257308A priority patent/AU2010257308B2/en
Priority to US13/077,980 priority patent/US8816051B2/en
Priority to JP2011170597A priority patent/JP5349552B2/ja
Priority to US14/444,859 priority patent/US9439974B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F10/00—Homopolymers and copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB0316294.8A 2003-07-11 2003-07-11 Conjugated biological molecules and their preparation Ceased GB0316294D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GBGB0316294.8A GB0316294D0 (en) 2003-07-11 2003-07-11 Conjugated biological molecules and their preparation
ES09167191.7T ES2632515T3 (es) 2003-07-11 2004-07-12 Moléculas biológicas conjugadas y su preparación
PL04743335T PL1648518T3 (pl) 2003-07-11 2004-07-12 Skoniugowane cząsteczki biologiczne i ich wytwarzanie
AU2004257448A AU2004257448B2 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
AT04743335T ATE440620T1 (de) 2003-07-11 2004-07-12 Konjugierte biologische moleküle und ihre herstellung
EP10175140.2A EP2253330B1 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
KR1020067000278A KR101152500B1 (ko) 2003-07-11 2004-07-12 접합된 생물학적 분자 및 그의 제조방법
DK04743335T DK1648518T3 (da) 2003-07-11 2004-07-12 Konjugerede biologiske molekyler og deres fremstilling
DK09167191.7T DK2133099T3 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
ES10175143.6T ES2542531T3 (es) 2003-07-11 2004-07-12 Procedimiento de preparación de moléculas biológicas conjugadas
US10/564,340 US7595292B2 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
CN2010101399434A CN101792525B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备
JP2006518372A JP4958549B2 (ja) 2003-07-11 2004-07-12 複合生物学的分子及びそれらの調製
ES10175140.2T ES2549427T3 (es) 2003-07-11 2004-07-12 Moléculas biológicas conjugadas y su preparación
DE602004022824T DE602004022824D1 (de) 2003-07-11 2004-07-12 Konjugierte biologische moleküle und ihre herstellung
EP20100175143 EP2277550B1 (en) 2003-07-11 2004-07-12 Process for the preparation of conjugated biological molecules.
DK10175143.6T DK2277550T3 (en) 2003-07-11 2004-07-12 A process for the preparation of conjugated biological molecules
EP09167191.7A EP2133099B1 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
PL10175140T PL2253330T3 (pl) 2003-07-11 2004-07-12 Skoniugowane cząsteczki biologiczne i ich otrzymywanie
ES04743335T ES2331004T3 (es) 2003-07-11 2004-07-12 Moleculas biologicas conjugadas y su preparacion.
CN2004800198144A CN1822860B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备
EP04743335A EP1648518B1 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
DK10175140.2T DK2253330T3 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
PCT/GB2004/002994 WO2005007197A2 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
US12/458,931 US7939630B2 (en) 2003-07-11 2009-07-28 Conjugated biological molecules and their preparation
AU2010257308A AU2010257308B2 (en) 2003-07-11 2010-12-20 Conjugated biological molecules and their preparation
US13/077,980 US8816051B2 (en) 2003-07-11 2011-03-31 Conjugated biological molecules and their preparation
JP2011170597A JP5349552B2 (ja) 2003-07-11 2011-08-04 複合生物学的分子及びそれらの調製
US14/444,859 US9439974B2 (en) 2003-07-11 2014-07-28 Conjugated biological molecules and their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316294.8A GB0316294D0 (en) 2003-07-11 2003-07-11 Conjugated biological molecules and their preparation

Publications (1)

Publication Number Publication Date
GB0316294D0 true GB0316294D0 (en) 2003-08-13

Family

ID=27742023

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0316294.8A Ceased GB0316294D0 (en) 2003-07-11 2003-07-11 Conjugated biological molecules and their preparation

Country Status (13)

Country Link
US (4) US7595292B2 (enExample)
EP (4) EP2133099B1 (enExample)
JP (2) JP4958549B2 (enExample)
KR (1) KR101152500B1 (enExample)
CN (2) CN1822860B (enExample)
AT (1) ATE440620T1 (enExample)
AU (2) AU2004257448B2 (enExample)
DE (1) DE602004022824D1 (enExample)
DK (4) DK1648518T3 (enExample)
ES (4) ES2549427T3 (enExample)
GB (1) GB0316294D0 (enExample)
PL (2) PL2253330T3 (enExample)
WO (1) WO2005007197A2 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5207590B2 (ja) 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
ES2533695T3 (es) * 2004-03-02 2015-04-14 Seattle Genetics, Inc. Anticuerpos cargados parcialmente y métodos para su conjugación
KR20080068004A (ko) * 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
BRPI0707425A2 (pt) * 2006-02-01 2011-05-03 Arana Therapeutics Ltd construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
WO2008098930A1 (en) * 2007-02-14 2008-08-21 Biocompatibes Uk Limited Derivatisation of biological molecules
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8658148B2 (en) 2007-06-22 2014-02-25 Genzyme Corporation Chemically modified dendrimers
TWI360535B (en) * 2007-08-30 2012-03-21 Univ Nat Sun Yat Sen Sulfur-containing compound, method of preparation
JP5933923B2 (ja) * 2007-10-09 2016-06-22 ポリテリクス リミテッド 新規な複合タンパク質及びペプチド
ES2466340T3 (es) * 2008-04-24 2014-06-10 Cantab Biopharmaceuticals Patents Limited Conjugados de Factor IX con semividas extendidas
RU2016108598A (ru) 2008-06-30 2018-11-23 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
MX2011000009A (es) 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
KR101763559B1 (ko) 2008-07-21 2017-08-14 폴리테릭스 리미티드 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법
GB0817978D0 (en) * 2008-10-01 2008-11-05 Imp Innovations Ltd Peptides
EA201170647A1 (ru) * 2008-11-04 2011-12-30 Янссен Фармацевтика Нв Пептиды-агонисты crhr2 и их использование
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
US10370245B2 (en) 2009-06-22 2019-08-06 Sanford-Burnham Medical Research Institute Methods and compositions using peptides and proteins with C-terminal elements
GB0916576D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
GB0916578D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
FI124016B (fi) * 2009-10-26 2014-01-31 Vapo Oy Menetelmä biomassakuivattimessa käytetyn kuivatusilman lämmittämiseksi välipiirinesteen avulla sekä vesi-glykoliseoksen tai sitä vastaavan jäätymättömän välipiirinesteen käyttö biomassakuivattimessa käytetyn kuivatusilman lämmittämiseksi
WO2011057027A2 (en) 2009-11-04 2011-05-12 Janssen Pharmaceutica Nv Method for treating heart failure with stresscopin-like peptides
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
CA2837588A1 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US20150086524A1 (en) 2012-04-16 2015-03-26 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
EP2861261A2 (en) * 2012-06-19 2015-04-22 Polytherics Limited Process for preparation of antibody conjugates and antibody conjugates
IN2015DN02349A (enExample) 2012-10-24 2015-08-28 Polytherics Ltd
NO2789793T3 (enExample) 2012-10-24 2018-01-27
CN104853781B (zh) 2012-11-30 2017-10-24 诺华股份有限公司 从含二硫化物的蛋白质制备缀合物的方法
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
EP2968593B1 (en) 2013-03-15 2024-11-20 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
GB201308738D0 (en) * 2013-05-15 2013-06-26 Polytherics Ltd Novel polymer conjugates
MX373528B (es) 2013-08-26 2020-04-21 Regeneron Pharma Composiciones farmacéuticas que contienen diasterómeros macrólidos, métodos para su síntesis y usos terapéuticos.
KR20160055253A (ko) 2013-09-12 2016-05-17 할로자임, 아이엔씨 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
BR112015032713B1 (pt) 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
BR112016007736B1 (pt) 2013-10-11 2022-09-27 Mersana Therapeutics, Inc Armação polimérica, e, composição farmacêutica
IL245009B (en) 2013-10-11 2022-08-01 Asana Biosciences Llc Protein-polymer-drug conjugates
EA201691075A1 (ru) * 2013-11-26 2016-09-30 Новартис Аг Способы оксимной конъюгации с кетон-модифицированными полипептидами
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
EP3145552B1 (en) 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
HK1231367A1 (zh) 2014-06-02 2017-12-22 Regeneron Pharmaceuticals, Inc. 抗体药物偶联物、试剂和制备方法及其治疗用途
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
ES2885854T3 (es) 2014-10-14 2021-12-15 Polytherics Ltd Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG
CA2975810C (en) * 2015-02-05 2025-05-13 Ablynx Nv NANOBODY DIMERS LINKED VIA C-TERMINAL ENGINEERED CYSTEINS
SG11201707148PA (en) 2015-03-27 2017-10-30 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
US10098960B2 (en) 2015-04-03 2018-10-16 Ucl Business Plc Polymer conjugate
US10509035B2 (en) 2015-08-07 2019-12-17 Gamamabs Pharma Sa Antibodies, antibody drug conjugates and methods of use
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
US10975161B2 (en) 2016-01-12 2021-04-13 Crescendo Biologics Limited Molecules that bind prostate specific membrane antigen (PSMA)
GB201601136D0 (en) 2016-01-21 2016-03-09 Mörgelin Matthias And Abdillahi Suado M Novel polypeptides and medical uses thereof
CN108779127B (zh) 2016-01-25 2022-07-05 里珍纳龙药品有限公司 美登素类化合物衍生物、其偶联物和使用方法
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20180121786A (ko) 2016-03-29 2018-11-08 오비아이 파머 인코퍼레이티드 항체, 제약 조성물 및 방법
WO2017178828A1 (en) 2016-04-14 2017-10-19 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
KR20250048399A (ko) 2016-04-22 2025-04-08 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
ES2965349T3 (es) 2016-06-06 2024-04-12 Abzena Uk Ltd Anticuerpos, usos de los mismos y conjugados de los mismos
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
GB201615725D0 (en) 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
CA3044274A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US10772971B2 (en) 2017-06-22 2020-09-15 Mersana Therpeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB201909298D0 (en) 2019-06-28 2019-08-14 Colzyx Ab Novel compositions and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
GB202016456D0 (en) 2020-10-16 2020-12-02 Colzyx Ab Novel bioactive peptide combinations and uses thereof
CN119836305A (zh) 2022-07-15 2025-04-15 费恩治疗有限公司 抗体-药物缀合物
CN115304524A (zh) * 2022-07-21 2022-11-08 湖南大学 一种β-酰基烯丙基甲基砜类化合物及其高效合成方法
TW202421207A (zh) 2022-09-30 2024-06-01 大陸商上海迪諾醫藥科技有限公司 苯并氮雜卓衍生物、含其的偶聯物及其應用
AU2023393382A1 (en) 2022-12-14 2025-06-19 Pheon Therapeutics Ltd Cytotoxic compounds
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US680343A (en) * 1899-04-15 1901-08-13 Johan Peter Moeller Glove.
US3828412A (en) * 1971-03-19 1974-08-13 Dunham Bush Inc Method of forming high integrity epoxy joint between aluminum tubes
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0298101A1 (en) 1987-01-15 1989-01-11 Celltech Limited Thiol-reactive cross-linking reagents
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2247656T3 (es) 1989-04-19 2006-03-01 Enzon, Inc. Un proceso para formar un polipeptido modificado que comprende un polipeptido y un oxido de polialquileno.
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP3693671B2 (ja) 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
WO1994004193A1 (en) 1992-08-21 1994-03-03 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5786387A (en) * 1994-03-23 1998-07-28 Meiji Seika Kabushiki Kaisha Lipid double-chain derivative containing polyoxyethylene
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
GB9713979D0 (en) 1997-07-03 1997-09-10 Univ Nottingham Method for attaching peg to macromolecules
JP4078032B2 (ja) * 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
SI1421956T1 (sl) * 1998-04-28 2007-10-31 Serono Lab Postopek za stopenjsko vezavo polietilenglikola (peg) na polipeptid
AU4934299A (en) * 1999-07-15 2001-02-05 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
WO2001017515A1 (en) 1999-09-03 2001-03-15 School Of Pharmacy, University Of London Degradable polymers
US6828412B1 (en) 1999-09-03 2004-12-07 School Of Pharmacy, University Of London Degradable polymers
US6803438B1 (en) 1999-09-08 2004-10-12 Polytherics Limited Uniform molecular weight polymers
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
GB0400264D0 (en) 2004-01-07 2004-02-11 Polytherics Ltd Complexes
WO2008098930A1 (en) 2007-02-14 2008-08-21 Biocompatibes Uk Limited Derivatisation of biological molecules
JP5933923B2 (ja) 2007-10-09 2016-06-22 ポリテリクス リミテッド 新規な複合タンパク質及びペプチド
KR101763559B1 (ko) 2008-07-21 2017-08-14 폴리테릭스 리미티드 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
GB0912485D0 (en) 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents

Also Published As

Publication number Publication date
CN1822860B (zh) 2010-05-05
JP2007527382A (ja) 2007-09-27
US20090298154A1 (en) 2009-12-03
CN101792525B (zh) 2012-06-06
AU2010257308A1 (en) 2011-01-13
US9439974B2 (en) 2016-09-13
ES2632515T3 (es) 2017-09-13
JP5349552B2 (ja) 2013-11-20
JP2012021003A (ja) 2012-02-02
DK2133099T3 (en) 2017-07-31
DE602004022824D1 (de) 2009-10-08
WO2005007197A3 (en) 2005-03-31
AU2004257448A1 (en) 2005-01-27
US20060210526A1 (en) 2006-09-21
KR101152500B1 (ko) 2012-07-05
EP2253330A2 (en) 2010-11-24
EP1648518B1 (en) 2009-08-26
EP2133099A2 (en) 2009-12-16
AU2010257308B2 (en) 2012-01-12
AU2004257448B2 (en) 2010-09-23
KR20060054286A (ko) 2006-05-22
EP2133099B1 (en) 2017-04-19
ES2542531T3 (es) 2015-08-06
DK1648518T3 (da) 2009-11-09
US7595292B2 (en) 2009-09-29
EP2277550A1 (en) 2011-01-26
ES2331004T3 (es) 2009-12-18
CN101792525A (zh) 2010-08-04
PL2253330T3 (pl) 2016-01-29
US7939630B2 (en) 2011-05-10
DK2253330T3 (en) 2015-10-19
EP1648518A2 (en) 2006-04-26
US8816051B2 (en) 2014-08-26
US20110182855A1 (en) 2011-07-28
EP2133099A3 (en) 2010-03-10
EP2253330A3 (en) 2011-03-09
EP2253330B1 (en) 2015-08-19
WO2005007197A2 (en) 2005-01-27
DK2277550T3 (en) 2015-08-03
ES2549427T3 (es) 2015-10-28
PL1648518T3 (pl) 2010-02-26
US20140369960A1 (en) 2014-12-18
CN1822860A (zh) 2006-08-23
EP2277550B1 (en) 2015-04-29
ATE440620T1 (de) 2009-09-15
JP4958549B2 (ja) 2012-06-20

Similar Documents

Publication Publication Date Title
GB0316294D0 (en) Conjugated biological molecules and their preparation
CN101200504B (zh) 高分子巯基化改性衍生物及其交联材料
CA2191971A1 (en) Pegylation reagents and compounds formed therewith
WO2005065239A3 (en) Novel recombinant proteins with n-terminal free thiol
EA200000607A1 (ru) Конъюгаты эритропоэтина
EP2374481A3 (en) Novel reagents and method for conjugating biological molecules
AU5289096A (en) Polyethylene oxides having saccharide residue at one end and different functional group at another end, and process for producing the same
BR0116381A (pt) Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina
ATE307844T1 (de) Kohlenwasserstoffendgruppen enthaltende polyether-polyamid-blockcopolymere und deren anwendung
FI972326A0 (fi) Uusi amidinonaftyylijohdannainen tai sen suola
BR9915651A (pt) Processo para a preparação de ácidos alcanossulfÈnicos.
DE59408399D1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
DE69920221D1 (de) Polypeptid-polymer konjugat
EP1149830A4 (en) PROCESS FOR PRODUCING SULFIDE COMPOUNDS
ATE489356T1 (de) Asymmetrischer kupferkomplex und dessen verwendung in cyclopropanierungsreaktion
EP1167418A4 (en) POLYOXYETHYLENE DERIVATIVES WITH A TERMINAL, PROTECTED AMINOGROUP AND METHOD FOR THE PRODUCTION THEREOF
BR0210542A (pt) Processo para preparação de derivados de cicloexanol
ATE553141T1 (de) Neues polymer und herstellungsverfahren dafür
EP0739905A4 (en) POLYMERIZATION CATALYST AND METHOD FOR PRODUCING POLYSTYRENE WITH THIS CATALYST
DE69607890D1 (de) Aromatische Hydroxamsäure-Verbindungen, ihre Herstellung und Verwendung
Bauer Hydroxocobalamins as biologically compatible donors of nitric oxide implicated in the acceleration of wound healing
EP1270634A4 (en) RESIN COMPOSITION CONTAINING AROMATIC EPISULFIDE AND OPTICAL MATERIAL
ATE232240T1 (de) Verfahren zur herstellung von l-allysin acetal
EP0742258A3 (en) Compatibility agent and method of its production
WO2002092615A3 (en) Compositions and methods for array-based genomic nucleic acid analysis of biological molecules

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)